Triple-Drug cocktail takes on advanced melanoma
NCT ID NCT04091750
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II study tests a combination of three drugs—nivolumab, ipilimumab, and cabozantinib—in 14 people with advanced melanoma that cannot be surgically removed. Participants receive the drugs for up to two years. The main goal is to see how long the cancer stays under control. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced melanoma that cannot be removed by surgery.
What could go wrong
This is a very small, early-phase study with only 14 participants, so results may not apply to everyone. The drug combination can cause significant side effects, and it is not yet known if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
Medstar Franklin Square Medical Center, Harry and Jeanette Weinberg Cancer Institute
Baltimore, Maryland, 21237, United States